PI-RADS 3, 4 or 5: what your prostate MRI result means
A PI-RADS score estimates how likely an area on your MRI is to be a cancer that matters. It is not a diagnosis. Here is what each score means, and what usually happens next.
In this article
A prostate MRI can answer a big question, but it rarely answers every question on its own.
When a report says PI-RADS 3, 4 or 5, the score is estimating how likely it is that an area of the prostate is clinically significant prostate cancer: a cancer more likely to need treatment rather than simple monitoring.
That estimate matters, because MRI is now central to diagnosis. In UK practice, men referred with a possible prostate cancer, usually after a raised PSA, will normally have an MRI before any biopsy is planned. The scan gives a clear view of the prostate and helps decide whether more tests are needed.
What a prostate MRI is looking for
A prostate MRI examines the gland in detail, looking for areas that behave differently from normal tissue. Multiparametric MRI does this by combining several types of image: one showing the anatomy, one showing how freely water moves within the tissue, and sometimes one taken after a contrast injection. Together, they can reveal an area that deserves a closer look.
This helps in two ways. MRI can spare men with reassuring scans an unnecessary biopsy. And if there is a suspicious area, the biopsy can be aimed straight at it, rather than sampling the prostate blindly. That shift has changed the diagnostic pathway for the better.
How the PI-RADS score works
PI-RADS stands for Prostate Imaging Reporting and Data System. It was developed to make prostate MRI reports more consistent, and to focus attention on the chance of clinically significant cancer.
The higher the score, the greater the suspicion. A high score does not guarantee cancer, and a low score does not make cancer impossible. Scores of 1 and 2 are usually reassuring. The scores that prompt most discussion are 3, 4 and 5.
| PI-RADS score | What it generally means | What often happens next |
|---|---|---|
| 3Equivocal | Uncertain: could be significant cancer, but MRI alone is not convincing | Biopsy or monitoring, decided with your PSA density, age, family history and previous results |
| 4High suspicion | Clinically significant cancer is likely | Biopsy is commonly recommended |
| 5Very high suspicion | Clinically significant cancer is very likely | Biopsy is strongly advised, with targeted samples from the MRI lesion |
PI-RADS or Likert? Many UK hospitals report prostate MRI using a 1 to 5 Likert score instead of, or alongside, PI-RADS. The two systems are not identical, but the numbers are read in much the same way, and everything in this article applies to both.
What a PI-RADS 3 result means
PI-RADS 3 is the hardest category for many men, because it does not give a clear yes or no. It is described as equivocal. In plain terms, the scan shows something that could be clinically significant cancer, but the MRI evidence alone is not strong enough to be confident either way.
That uncertainty is why a PI-RADS 3 result leads to a more individual discussion. A specialist will look closely at your PSA level and PSA density, the size and position of the lesion, your family history, ethnicity, age and symptoms, and whether you have had a biopsy before.
Pathways differ. In some, a PI-RADS 3 lesion is enough to trigger a biopsy. In others, the threshold is set higher. Research suggests that using PI-RADS 4 rather than 3 as the cut-off can reduce the number of biopsies and the detection of insignificant cancers, without clearly missing more significant ones. That is useful, but it does not make PI-RADS 3 harmless. It shows why the next step needs judgement.
A PI-RADS 3 score means uncertainty, not safety.
What a PI-RADS 4 result means
PI-RADS 4 indicates a high suspicion of clinically significant prostate cancer. The MRI appearance is more convincing, so the balance usually shifts towards biopsy rather than waiting.
Even so, PI-RADS 4 is not proof of cancer. Some PI-RADS 4 areas turn out to be inflammation, benign changes or lower-risk disease. MRI is powerful, but looking at tissue under the microscope remains the way to confirm what an area really is.
That is why a targeted biopsy is usually recommended for PI-RADS 4. The MRI pinpoints the area, and the biopsy samples it directly, often combined with systematic samples from the rest of the prostate for accuracy.
What a PI-RADS 5 result means
PI-RADS 5 is the most suspicious category. It suggests a very high likelihood that the area is clinically significant prostate cancer.
For most men, a PI-RADS 5 report leads to a clear conversation about biopsy and its timing. The aim is not to alarm you, but to move promptly towards certainty. Only a biopsy can confirm the diagnosis and show the grade of any cancer found, and that is what treatment decisions are based on.
Why biopsy decisions are not based on MRI alone
MRI sits within a wider clinical picture. A specialist is answering two questions at once: is there cancer, and if so, is it the kind that needs treatment? The same PI-RADS 3 lesion can be approached differently in two men, depending on everything else.
When biopsy is being discussed, these details usually shape the decision:
- PSA level and PSA density: a PSA result is more or less concerning once it is related to the size of the prostate. A PSA density above about 0.15 generally raises concern.
- Prostate examination: a normal examination is reassuring, while an abnormal one increases concern.
- Family history: a strong family history lowers the threshold for further testing.
- Previous biopsies: a prior negative biopsy can change how a borderline MRI is read, but it does not always settle the question.
- Your health and preferences: the next step should make sense medically and practically for you.
If you are unsure what your PSA result means on its own, my articles on a PSA of 3, a PSA of 5 and a PSA of 10 explain how the numbers are interpreted.
What happens if a prostate biopsy is advised
If a biopsy is recommended, the MRI guides the plan. The suspicious area can be targeted, giving the biopsy the best chance of answering the real question.
Most UK centres now use a transperineal biopsy, where samples are taken through the skin between the scrotum and the back passage rather than through the bowel, which lowers the risk of infection. It can be used for targeted samples, systematic samples or both. I explain what to expect in transperineal biopsy: what is it, and does it hurt?
From my own research
How best to target an MRI lesion, and whether systematic samples still add value alongside targeted ones, are questions I have studied directly. I have co-authored two studies on exactly this, both published in the Journal of Urology. See my publications
A biopsy answers several questions at once:
- whether cancer is present
- whether it is clinically significant
- how aggressive the cells look (the Gleason score or Grade Group)
- how much of the prostate is involved
- whether monitoring or treatment is the better path
Those answers shape every later decision, from active surveillance to robotic surgery, radiotherapy or focal therapy, which is only possible when the cancer is clearly visible on MRI.
What if a PI-RADS 3 lesion is not biopsied straight away?
Not every PI-RADS 3 result leads directly to biopsy. Sometimes careful monitoring is a sensible and safe next step: repeat PSA tests, a review of PSA density, a repeat MRI after a set interval, or discussion at a multidisciplinary team meeting.
"Uncertain" is not an easy result to live with. But monitoring is not neglect. It means the current evidence does not yet justify an invasive test, while recognising that follow-up matters.
If a biopsy has already been negative but the MRI remains concerning, a repeat biopsy may need to be discussed. A negative biopsy is reassuring, but it is not always the end of the story.
How to read the wording in your MRI report
It is natural to focus on the number and skip the rest of the report, but other wording can be just as useful at your appointment.
- Lesion: simply an area that looks different from the surrounding tissue.
- Peripheral zone and transition zone: different regions of the prostate. The scoring weighs findings differently depending on where the lesion sits.
- Capsule: the outer edge of the prostate.
- Extraprostatic extension: a sign that the abnormal area may extend beyond the prostate's edge, which matters for staging and surgical planning.
The report may also describe the lesion's size, shape and how sharply it is defined. These details help the radiologist arrive at the score, and help the urologist plan how to target it. If the wording feels technical, take the report to your appointment and ask for it to be explained line by line. That is an entirely reasonable request.
Questions to ask after a prostate MRI result
A short list of questions can turn an anxious appointment into a structured discussion:
- What is my exact PI-RADS (or Likert) score, and where is the lesion?
- Do my PSA level and PSA density make this more or less concerning?
- Is a biopsy recommended now, or is monitoring a reasonable option?
- If I have a biopsy, will it be targeted, systematic, or both?
- If we do not biopsy now, what is the follow-up plan?
- Has my case been, or should it be, reviewed by a multidisciplinary team?
These questions keep the focus where it belongs: on what the MRI means for your risk, your next step and your timeframe. If you would like an independent view of your scan, I offer second opinions in person or by video.
